BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 11800507)

  • 21. Efficacy and safety of zolpidem extended release in elderly primary insomnia patients.
    Walsh JK; Soubrane C; Roth T
    Am J Geriatr Psychiatry; 2008 Jan; 16(1):44-57. PubMed ID: 18165461
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Zolpidem in the treatment of transient insomnia: a double-blind, randomized comparison with placebo.
    Roth T; Roehrs T; Vogel G
    Sleep; 1995 May; 18(4):246-51. PubMed ID: 7618022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder.
    Fava M; Asnis GM; Shrivastava R; Lydiard B; Bastani B; Sheehan D; Roth T
    J Clin Psychopharmacol; 2009 Jun; 29(3):222-30. PubMed ID: 19440075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of eight months of nightly zolpidem: a prospective placebo-controlled study.
    Randall S; Roehrs TA; Roth T
    Sleep; 2012 Nov; 35(11):1551-7. PubMed ID: 23115404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multicenter, double-blind, controlled comparison of zolpidem and triazolam in elderly patients with insomnia.
    Roger M; Attali P; Coquelin JP
    Clin Ther; 1993; 15(1):127-36. PubMed ID: 8458042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Zolpidem extended-release.
    Moen MD; Plosker GL
    CNS Drugs; 2006; 20(5):419-26; discussion 427-8. PubMed ID: 16696581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gender influences on efficacy and safety of sublingual zolpidem tartrate for middle-of-the-night awakening in insomnia.
    Roth T; Steinberg F; Singh NN; Moline M
    Hum Psychopharmacol; 2014 Jan; 29(1):25-30. PubMed ID: 24424704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group.
    Elie R; Rüther E; Farr I; Emilien G; Salinas E
    J Clin Psychiatry; 1999 Aug; 60(8):536-44. PubMed ID: 10485636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Efficacy and safety of modified release zolpidem in patients with chronic insomnia].
    Jiménez-Genchi A;
    Rev Med Inst Mex Seguro Soc; 2012; 50(5):529-36. PubMed ID: 23282267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary Insomnia.
    Krystal AD; Durrence HH; Scharf M; Jochelson P; Rogowski R; Ludington E; Roth T
    Sleep; 2010 Nov; 33(11):1553-61. PubMed ID: 21102997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and tolerance of zolpidem in the treatment of disturbed sleep: a post-marketing surveillance of 16944 cases.
    Hajak G; Bandelow B
    Int Clin Psychopharmacol; 1998 Jul; 13(4):157-67. PubMed ID: 9727726
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized, double blind trial of zolpidem 10 mg versus triazolam 0.25 mg for treatment of insomnia in general practice.
    Rosenberg J; Ahlstrøm F
    Scand J Prim Health Care; 1994 Jun; 12(2):88-92. PubMed ID: 7973199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preference of insomniac patients between a single dose of zolpidem 10 mg versus zaleplon 10 mg.
    Allain H; Bentué-Ferrer D; Breton SL; Polard E; Gandon JM
    Hum Psychopharmacol; 2003 Jul; 18(5):369-74. PubMed ID: 12858323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A double-blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients.
    Shaw SH; Curson H; Coquelin JP
    J Int Med Res; 1992 Apr; 20(2):150-61. PubMed ID: 1521671
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of insomnia related to depressive disorders. Effects of zolpidem versus flunitrazepam administration and withdrawal evaluated in a double-blind study].
    Guazzelli M; Ciapparelli A; Balsamo EL; Gemignani A; Sarteschi P
    Minerva Psichiatr; 1993 Sep; 34(3):193-203. PubMed ID: 8302193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polysomnographic study of intermittent zolpidem treatment in primary sleep maintenance insomnia.
    Parrino L; Smerieri A; Giglia F; Milioli G; De Paolis F; Terzano MG
    Clin Neuropharmacol; 2008; 31(1):40-50. PubMed ID: 18303490
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sleep in patients with chronic primary insomnia during long-term zolpidem administration and after its withdrawal.
    Monti JM; Monti D; Estévez F; Giusti M
    Int Clin Psychopharmacol; 1996 Dec; 11(4):255-63. PubMed ID: 9031992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 2-week efficacy and safety study of gaboxadol and zolpidem using electronic diaries in primary insomnia outpatients.
    Hajak G; Hedner J; Eglin M; Loft H; Stórustovu SI; Lütolf S; Lundahl J;
    Sleep Med; 2009 Aug; 10(7):705-12. PubMed ID: 19346160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pilot controlled double-blind study of the hypnotic effects of zolpidem in patients with chronic 'learned' insomnia: psychometric and polysomnographic evaluation.
    Herrmann WM; Kubicki ST; Boden S; Eich FX; Attali P; Coquelin JP
    J Int Med Res; 1993; 21(6):306-22. PubMed ID: 8143886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new sublingual formulation of zolpidem for the treatment of sleep-onset insomnia.
    Staner L; Danjou P; Luthringer R
    Expert Rev Neurother; 2012 Feb; 12(2):141-53. PubMed ID: 22288669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.